



BeOne Medicines Ltd.

百濟神州有限公司

(a corporation incorporated under the laws of Switzerland)

(根據瑞士法律註冊成立的公司)

(Stock Code 股份代號: 06160)

September 10, 2026

Dear registered shareholder(s),

Reminder Letter regarding the Arrangement of Electronic Dissemination of Corporate Communications

With reference to the notification letter dated February 28, 2024 titled “Arrangement of Electronic Dissemination of Corporate Communications”, BeOne Medicines Ltd. (the “**Company**”) is writing to remind you that the Company has adopted electronic dissemination of corporate communications (the “**Corporate Communications**”), which include any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to interim and annual reports, notice of general meetings, proxy forms, circulars, and listing documents.

Please note that both English and Chinese versions of all future Corporate Communications will be available electronically on the website of the Company at <https://hkexir.beonemedicines.com/> and the HKEXnews website at www.hkexnews.hk (the “**Electronic Versions**”) in place of printed copies, unless otherwise specified below. The Company will not send you any email notification regarding the publication of Corporate Communications or any Corporate Communications in printed form, unless otherwise specified below. You are encouraged to proactively monitor the availability and access the Electronic Versions of all future Corporate Communications yourself.

Notwithstanding the above, to the extent required under applicable rules, including rules of the U.S. Securities and Exchange Commission, the Company may mail printed copies of proxy materials for general meetings of shareholders, including Proxy Statement/Circular, Form of Proxy, Annual Report on Form 10-K, or important notice regarding the internet availability of proxy materials for general meetings of shareholders to you.

If you want to receive the Corporate Communications in printed form, please complete the enclosed reply form (the “**Reply Form**”) and send it to the Company’s Hong Kong share registrar (the “**Share Registrar**”), Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong, or send an email to BeOne.ecom@computershare.com.hk specifying your name, address and request to receive the Corporate Communications in printed form. Please note that such instruction shall be valid for one year starting from the receipt date of your instruction and will expire thereafter.

If you want to receive Actionable Corporate Communications in electronic form, which include any corporate communication that seeks instructions from issuer’s securities holders on how they wish to exercise their rights or make an election as the issuer’s securities holder, please review and complete processes set out below.

To ensure timely receipt of the Actionable Corporate Communications, the Company recommends you provide your email address by scanning your personalized QR code printed on the Reply Form. Alternatively, you may sign and return the Reply Form to the Share Registrar at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong.

If the Company does not receive a functional email address in your reply, until such time that the functional email address is provided to the Share Registrar, the Company will send the Actionable Corporate Communications in printed form to you.

Please note that you will not receive any email notification regarding the publication of Corporate Communications and need to proactively check the Company’s website and/or the HKEXnews website to keep up with the publication of Corporate Communications.

Should you have any queries relating to this letter, please contact the Share Registrar at (852)2862 8688 during business hours from 9:00 a.m. to 6:00 p.m. (Hong Kong time), Mondays to Fridays, excluding Hong Kong public holidays.

Yours faithfully,
By order of the Board
BeOne Medicines Ltd.
Mr. John V. Oyler
Chairman

各位登記股東：

以電子方式發布公司通訊安排的提示信函

根據日期為 2024 年 2 月 28 日有關「以電子方式發布公司通訊之安排」之通知信函所述，百濟神州有限公司（「**公司**」）謹此提醒 閣下，公司已採用以電子方式發布公司通訊（「**公司通訊**」）之安排，該公司通訊是指公司發布或將要發布以供其任何證券的持有人參照或採取行動的任何文件，包括但不限於中期報告、年度報告、股東會議通知、委任表格、通函以及上市文件。

請注意，除下文另行說明，所有未來公司通訊的英文版和中文版將在公司網站 <https://hkexir.beonemedicines.com/> 和披露易網站 www.hkexnews.hk（「**電子版本**」）上提供，以代替印刷本。公司將不會通過電郵方式向 閣下發出公司通訊電子版本的登載通知，亦不會向 閣下以印刷本形式發送任何公司通訊，下文另行說明的情況除外。公司鼓勵閣下主動留意並自行瀏覽所有日後的公司通訊和登載情況。

儘管有上述安排，根據適用規則的要求（包括美國證券交易委員會的規則），公司將向 閣下寄發印刷版的股東大會通函材料，包括通函、委任表格、年度報告 10-K 表格或股東大會通函材料可通過網路查閱之重要通知。

若 閣下希望收取公司通訊之印刷版，請填妥本函隨附之回條（「**回條**」）並交回公司的香港股份過戶登記處（「**股份過戶處**」）香港中央證券登記有限公司，地址為香港灣仔皇后大道東 183 號合和中心 17M 樓，或發送電子郵件至 BeOne.ecom@computershare.com.hk，並註明 閣下的姓名、地址以及收取公司通訊印刷版的要求。請注意，收取未來公司通訊印刷版之指示由收悉 閣下指示當日起計一年內有效，此後將過期。

若 閣下希望通過電子方式收取可供採取行動的公司通訊（指任何涉及要求發行人的證券持有人指示其擬如何行使其有關證券持有人的權利的公司通訊），請流覽及完成如下流程。

為確保及時收到可供採取行動的公司通訊，公司建議 閣下透過掃描回條上列印的 閣下專屬二維碼來提供 閣下的電子郵件地址。或者， 閣下也可以簽署回條並交回股份過戶處，地址為香港灣仔皇后大道東 183 號合和中心 17M 樓。

如果公司沒有收到 閣下的有效電子郵件地址，直至股份過戶處收到 閣下有效的電子郵件地址前，公司將以印刷本形式發送可供採取行動的公司通訊。

請注意， 閣下將不會通過電郵方式收到公司通訊的登載通知，閣下需主動留意公司網站和/或披露易網站以跟進公司通訊的登載情況。

如 閣下對本函件有任何疑問，請於辦公時間星期一至五（香港公眾假期除外）上午 9 時正至下午 6 時正（香港時間）其間致電股份過戶處(852)2862 8688 查詢

承董事會命
百濟神州有限公司
歐雷強先生
主席
謹啟

2026 年 9 月 10 日

REPLY FORM 回條

To: Computershare Hong Kong Investor Services Limited (the “Share Registrar”) 致：香港中央證券登記有限公司（「股份過戶處」）
17M Floor, Hopewell Centre 香港灣仔皇后大道東 183 號
183 Queen’s Road East, Wan Chai, Hong Kong 合和中心 17M 樓

(Please **choose ONLY ONE** of the options below)
(請從以下選項中只選擇其中一項)

Personalized QR Code
專屬二維碼

Option 1: Provide your email address for receipt of future Actionable Corporate Communications^(Note 3) of the Company via electronic dissemination by scanning your personalized QR code

選項 1： 掃描 閣下專屬二維碼提供 閣下之電子郵件地址，以接收公司通過電子方式發佈的可供採取行動的未來公司通訊 (附註 3)

You are **NOT required** to return this Reply Form if you choose Option 1.
如選擇了選項 1，閣下**無須**交回本回條。

Option 2: I/we hereby provide my/our email address in writing for receipt of future Actionable Corporate Communications^(Note 3) of the following listed company (the “Company”) via electronic dissemination.

選項 2: 本人/吾等現以書面提供本人/吾等之電子郵件地址，以確保收到以下上市公司（「公司」）通過電子方式發佈的可供採取行動的未來公司通訊^(附註 3)

Name of the listed company 上市公司名稱：

BeOne Medicines Ltd.
百濟神州有限公司

Email address 電郵地址: (Notes 3 / 附註 3)

[illegible]

Option 3: I/we hereby request for receipt of Corporate Communications* in printed form (Please mark "✓" in the below box if applicable)

選項 3: 本人/吾等現要求收取公司通訊*印刷版 (如適用, 請在以下方格內劃上「✓」號)

receive future Corporate Communications* in printed copy and noted that this instruction is valid only for one year starting from the receipt date of instruction. (Note 5)
收取未來公司通訊的印刷本，並已知悉本指示由收取指示日期起計一年內有效。(附註：5)

☐ Printed English version 英文印刷本 ☐ Printed Chinese version 中文印刷本 ☐ Printed English and Chinese versions 中、英文印刷本

Date:

日期：

Notes 附註:

1. Please complete all your details clearly. If your shares are held in joint names, all of the joint shareholders should jointly sign this Reply Form in order to be valid.
請清楚填妥 閣下之所有資料。如屬聯名股東，則本回條須由所有聯名股東聯名簽署，方為有效。
2. Any Reply Form with no signature or which is otherwise incorrectly completed will be void.
任何回條若未有簽署或在其他方面填寫不正確，則本回條將會作廢。
3. Actionable Corporate Communication is any corporate communication that seeks instructions from issuer's securities holders on how they wish to exercise their rights or make an election as the issuer's securities holder. It can take the form of a company notice or any other document that seeks instructions from the securities holder on how they wish to exercise their rights or make an election as the issuer's securities holder.
可行取行動的公司通訊指任何涉及要求發行人的證券持有人指示其擬如何行使有關證券持有人的權利的公司通訊。
4. If you provide more than one email address by QR code, email, reply form and/or other means, only the latest email address provided will be registered.
如 閣下通過二維碼、電郵、回條及/或其他方法提供多於一個的電子郵件地址，只有 閣下最後提供的電子郵件地址將會被用於登記。
5. If you mark "X" in the box in Option 3, no email address will be registered and only Corporate Communications* in printed form will be received.
如 閣下在選項 3 方格內劃上「X」號，將不會有電子郵件地址被登記，只有公司通訊*的印刷版會被收取。
6. For the avoidance of doubt, the Company does not accept any other instructions given on this Reply Form.
為免存疑，在本回條上的任何額外指示，公司將不予處理。
- * Under the Securities and Futures Commission's Communication Code, the Company will not respond to any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to the annual general meeting, interim report, notice of meeting, circular and proxy form.
除非常為註明，公司通訊乃指公司已發出或將予發出以尋求任何證券的持有人參照或採取行動的任何文件，其中包括但不限於年報、中期報告、會議通告、通函及代表委任表格。

PERSONAL INFORMATION COLLECTION STATEMENT 收集個人資料聲明

- (i) "Personal Information Collection Statement" (collecting personal data) in the Personal Data (Privacy) Ordinance, Chapter 486 of the Laws of Hong Kong ("PDPO").
- (ii) "Personal Data" has the same meaning as "personal data" in the Personal Data (Privacy) Ordinance, Chapter 486 of the Laws of Hong Kong ("PDPO").
- (iii) The meaning of the "Personal Data" and the meaning of the "personal data" in the Personal Data (Privacy) Ordinance, Chapter 486 of the Laws of Hong Kong ("PDPO") are the same.
- (iv) Your Personal Data provided in this Reply Form will be used in connection with, including but not limited to, the Company's electronic dissemination of Corporate Communications and to liaise with you on other matters relating to your holdings in the Company. Your supply of Personal Data to the Company is on a voluntary basis. In case of a failure to provide sufficient information, the Company may not be able to process your instruction and/or request as stated in this Reply Form.
- (v) 閣下向本公司提供個人資料，包括但不限於閣下向本公司以電子方式發布公司通訊及/或閣下持有的公司證券有關的其他事宜與閣下聯絡。閣下是自願向本公司提供個人資料。若閣下未能提供足夠資料，本公司可能無法處理閣下在本回覆表格所述的指示及/或要求。
- (vi) Your Personal Data may be disclosed or transferred by the Company to its subsidiaries, the Share Registrar, and/or other companies or bodies for any of the stated purposes, or when it is required to do so by law and will be retained for such period as may be necessary for our verification and record purposes.
- (vii) 閣下向本公司提供個人資料，包括但不限於閣下向本公司以電子方式發布公司通訊及/或閣下持有的公司證券有關的其他事宜與閣下聯絡。閣下是自願向本公司提供個人資料。若閣下未能提供足夠資料，本公司可能無法處理閣下在本回覆表格所述的指示及/或要求。
- (viii) You have the right to request access to and/or correction of your Personal Data in accordance with the provisions of the PDPO. Any such request for access to and/or correction of your Personal Data should be in writing, by mail to the Hong Kong Privacy Officer of the Share Registrar at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong or by email at PrivacyOfficer@computershare.com.hk.
- (ix) 閣下有權根據《個人資料(私隱)條例》向本公司索取及/或修改閣下的個人資料。任何該等索取及/或修改個人資料的要求均須以書面方式郵寄至股份過戶處(地址為香港灣仔皇后大道東183號合和中心17M樓)向香港隱私主任索取及/或修改個人資料。詳情請向本公司查詢。
- (x) You may request access to and/or correction of your Personal Data in accordance with the provisions of the PDPO. Any such request for access to and/or correction of your Personal Data should be in writing, by mail to the Hong Kong Privacy Officer of the Share Registrar at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong or by email at PrivacyOfficer@computershare.com.hk.

Mailing Label 郵寄標籤

Computershare Hong Kong Investor Services Limited
香港中央證券登記有限公司
Freepost No. 簡便回郵號碼 : 37
Hong Kong 香港

Please cut the mailing label and stick it on an envelope to return this form to us.

No postage is necessary if posted in Hong Kong.

當閣下寄回此回條時，請將郵寄標籤剪貼於信封上。
如在本港投寄，閣下無需支付郵費或貼上郵票。